Icodextrin solution - Innovata

Drug Profile

Icodextrin solution - Innovata

Alternative Names: Adept®; Extraneal; Icodextrin solution; Icodial®

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovata
  • Developer Baxter Healthcare Corporation; Shire
  • Class Glucans; Hexoses
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Kidney disorders
  • New Molecular Entity No

Highest Development Phases

  • Marketed Kidney disorders
  • Phase II Hypertriglyceridaemia
  • No development reported Heart failure

Most Recent Events

  • 11 Oct 2018 Phase- II development is ongoing in Hypertriglyceridaemia (In adults, In the elderly) in South Korea (Intraperitoneal) (NCT02166359)
  • 24 Jun 2018 Biomarkers information updated
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top